Platinum agents and mitomycin C-specific complications in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy

(2017) Eliza I-Lin Sin et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Prospective Quality of Life Study for Colorectal Cancer Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

(2016) Claramae Shulyn Chia et al.   ANNALS OF SURGICAL ONCOLOGY

Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors

(2016) Thibaut Charrier et al.   ANNALS OF SURGICAL ONCOLOGY

Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment

(2016) N. Bouhadjari et al.   EJSO

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours

(2016) N. Ansari et al.   EJSO

Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy

(2015) Véronique Kemmel et al.   ANNALS OF SURGICAL ONCOLOGY

Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis

(2014) Geert A. Simkens et al.   ANNALS OF SURGICAL ONCOLOGY

Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study

(2014) J. Spiliotis et al.   ANNALS OF SURGICAL ONCOLOGY

The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery

(2014) Hakeam A. Hakeam et al.   RENAL FAILURE

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Asian Patients: 100 Consecutive Patients in a Single Institution

(2013) Melissa Ching Ching Teo et al.   ANNALS OF SURGICAL ONCOLOGY

Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol

(2013) Anke M. J. Kuijpers et al.   ANNALS OF SURGICAL ONCOLOGY

Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: Early experience and phase 1 results

(2012) A. Hayes-Jordan et al.   PEDIATRIC BLOOD & CANCER

Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis

(2010) Kurt Van der Speeten et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Morbidity and Mortality With Cytoreductive Surgery and Intraperitoneal Chemotherapy

(2010) Faheez Mohamed et al.   CANCER JOURNAL

Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?

(2009) Terence C. Chua et al.   ANNALS OF SURGERY

Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C

(2009) Laura A. Lambert et al.   ANNALS OF SURGICAL ONCOLOGY

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience

(2009) Tristan D. Yan et al.   JOURNAL OF CLINICAL ONCOLOGY

Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

(2008) D. Elias et al.   BRITISH JOURNAL OF SURGERY